Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
about
Molecular genetics and immunohistochemistry characterization of uncommon and recently described renal cell carcinomasChildren's Oncology Group's 2013 blueprint for research: renal tumorsTargeted therapeutic strategies for the management of renal cell carcinomaThe metabolic basis of kidney cancerDiagnosis of adults Xp11.2 translocation renal cell carcinoma by immunohistochemistry and FISH assays: clinicopathological data from ethnic Chinese populationTivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methodsNon-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches.Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes.Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.PD-L1 expression in nonclear-cell renal cell carcinoma.The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.TFE3 Translocation-Associated Renal Cell Carcinoma Presenting as Avascular Necrosis of the Femur in a 19-Year-Old Patient: Case Report and Review of the Literature.Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategiesTMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancersCharacterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2.Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant articleNon-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusions: Clinical Features, Treatments and Prognosis.Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma.Modelling TFE renal cell carcinoma in mice reveals a critical role of WNT signalingRecent developments in the treatment of renal cell carcinoma.Renal Cell Carcinoma Associated with Xp11.2 Translocation/TFE3 Gene Fusion: A Rare Case Report with Review of the Literature.Renal cell carcinoma in children and adolescents.Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities.Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features.Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.Postoperative recurrence of adult renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case reportA Review of Translocation T(6;11) Renal Cell Carcinoma Tumors in the Adult Patient.A case of metastatic Xp11.2 translocation renal cell carcinoma successfully managed by cytoreductive nephrectomy followed by axitinib therapyCardiopulmonary bypass-assisted surgery for the treatment of Xp11.2 translocation/TFE3 gene fusion renal cell carcinoma with a tumor thrombus within the inferior vena cava: A case reportXp 11.2 translocation renal carcinoma in young adults; recently classified distinct subtype.Radiologic-pathologic correlation of renal cell carcinoma associated with Xp11.2 translocation.A phase 2 study of the sphingosine-1-phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma.The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review.Cutaneous metastases during an aggressive course of Xp11.2 translocation renal cell carcinoma in a teenager.
P2860
Q26752945-642DB523-2963-47FC-9775-FFE7119EDA2AQ27000449-C627BF5D-2EA8-4DFC-BC51-610AE69E383EQ27013846-49D88BC4-2B67-4F0B-96AD-2279FE7DF618Q27023273-4C48B64D-39A4-4B74-8ADB-89D0A49BDC9BQ31046172-CDF323EE-52E4-4489-BD1A-71346F4C4A3AQ33401272-4461019B-C9A7-4E66-84E3-710D6065B14AQ33761537-90326976-857A-4A93-AD7C-5D50C2ABA3CFQ34194075-25177632-A74C-4E44-A853-2636C82ED1A8Q34206517-80A7D7B8-7DB3-425F-9A7A-95A416687BABQ34206531-3B728146-E7B5-4639-B42E-DA4074F47AE0Q34882798-BC1C6682-CA81-4CAF-944D-813239C5C8AAQ35133904-A2408FEB-5F64-4763-B37A-8A5B640E8A90Q35293660-65D6A5B2-567C-477F-87DA-345B17BDA64EQ35315403-539DC066-0CD9-4537-8E97-4E97ECC9C0E8Q35632133-5EB39B1A-3292-48BF-9CCA-45B6FC2CE8D9Q36001179-649E0B4F-6632-4043-B37C-9150A942EBEBQ36105584-84975E16-781B-4E73-A926-14FA896D08DAQ36151526-C3D2B5CA-A89E-4AE7-8B60-4297D81C655CQ36182819-A308A0AD-F597-4FCB-B201-4AE7DE3CDF9CQ36205571-9992B6AE-2017-4785-A07D-56360941F2EFQ36341169-92201071-4B6A-4B2C-8C3B-532604F40556Q37284328-1F46AB38-EA7B-4D3D-B935-D40CBE362C64Q37300942-B73ACB7D-1858-4B07-95C8-54B56A60132CQ37435939-49B2FED0-463E-416E-A290-4AADC3F9D05DQ37812610-EDF3A914-8ABF-4ED6-BBEA-480749C2569BQ37836508-A753B85B-9837-425F-866C-D42DEE03ADB7Q38067125-D2E00547-ACEB-4406-A793-BD3B5C73D52EQ38168996-DD9E45FB-2B5B-4CCA-BE7F-F8749C2EECBFQ38388597-CD470968-6C58-4CA5-A5B5-F777F4162516Q38740145-4FA178E6-79AA-4EF0-A45A-82C19A82E14EQ39204706-877339B2-8401-4242-BA63-E5C7528F4B27Q39298566-EF4E78B9-B31C-4B40-9CCE-A2641E7E5785Q41126079-D7C008E5-04D9-4E2E-A0DD-B5A6654B7451Q41971524-0ADDA51A-35F6-411C-9583-577C66C8D251Q42215445-0BBC7DF6-1172-465C-B959-4A12754AB5C9Q42717006-48F7DF82-9AF1-41DE-A3B5-09D892BF07D4Q45867795-54339A4F-21AE-47D3-A19B-848D63468315Q46979728-308A6F1A-A9A1-4B61-B8E0-0AED4E0FAEC9Q47664030-954ED57D-1441-435A-879C-5F6EA8AF444CQ51157042-E93A175C-28E1-4C81-83DD-A2EC705E027F
P2860
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Targeted agents in metastatic ...... from the Juvenile RCC Network.
@en
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma
@nl
type
label
Targeted agents in metastatic ...... from the Juvenile RCC Network.
@en
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma
@nl
prefLabel
Targeted agents in metastatic ...... from the Juvenile RCC Network.
@en
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma
@nl
P2093
P2860
P356
P1433
P1476
Targeted agents in metastatic ...... from the Juvenile RCC Network.
@en
P2093
B Billemont
B Escudier
C Theodore
G G Malouf
G Schleiermacher
J Couturier
P2860
P304
P356
10.1093/ANNONC/MDQ029
P577
2010-02-12T00:00:00Z